Q-omics provides the consensus-scored PDSS1 profile across patient tissues and cancer cell-line models. PDSS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PDSS1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, PDSS1 RNA expression shows 19,444 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where PDSS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDSS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDSS1 survival associations across molecular data types. PDSS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDSS1 RNA expression–survival associations across cancer types. High PDSS1 expression shows unfavorable associations in LIHC, ACC, KIRP, BRCA, KICH and UCEC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PDSS1 RNA expression.
This table summarizes PDSS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDSS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDSS1 shows higher tumor expression in BLCA, STAD, LIHC, UCEC, LUSC and HNSC. The BLCA box plot shows higher PDSS1 RNA expression in tumor versus normal tissue (log2 FC = +1.338, t-test p < 0.001).
This table shows molecular features associated with PDSS1 in patient tissues and cancer cell lines. In patient samples, PDSS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDSS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
